Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
September 29, 2025 19:30 ET | Source: Nxera Pharma Tokyo, Japan and…
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
Company builds on earlier GLP-1 success with breakthrough AI-led insights into aging…
Natural Nine to Launch Feminine Cleanser in the First Half of Next Year, Targeting Overseas Consumers
HWASEONG, South Korea--(BUSINESS WIRE)--#BodyCareBrand--Natural Nine, a Korean body care brand, announced that…
Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell
Celebrates Indian Independence Day by Honoring the US-India Innovation PartnershipCAMBRIDGE, Mass.--(BUSINESS WIRE)--$HIND--Vyome…
Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress
Initial results from the First in Human (FIH) Phase 1 trial evaluating…
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co.,…
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older…
DP WORLD DELIVERS SAILGP FLEET TO PORT TARGETING NET-ZERO STATUS
DP World, SailGP's Global Smart Logistics Partner, delivers racing fleet into Port…
Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing
NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating…
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…